Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining a vaccine with QS21 may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus immune adjuvant QS21 in treating patients who have prostate cancer.

Key facts

Study ID

NCT00005632

Run by

Memorial Sloan Kettering Cancer Center

People needed

27

Starts

1999-06-01

Expected to finish

2009-03-01

Last updated by the study team

2013-01-31

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.